Three new lawsuits were filed this week against Eli Lilly and Novo Nordisk, the companies behind the leading GLP-1 medications. Courts have not yet unsealed the specific claims in any of the three cases, so patients and prescribers do not know what allegations are driving them. Still, the filings themselves are worth tracking. Litigation at this scale often shapes how manufacturers set prices, disclose risks, or defend their products, even before the underlying claims become public.
The Scully case names Eli Lilly and centers on either Mounjaro or Zepbound, the company's tirzepatide drugs for diabetes and weight loss. Because the claims are sealed, readers cannot yet tell whether the suit concerns side effects or another issue entirely. This lack of detail is common in the early stages of litigation, when initial filings are made before a court unseals the full complaint. Patients currently taking either drug do not need to change anything based on this filing alone, but it is one to watch as more information becomes available.
Cardenas v. Novo Nordisk follows a similar pattern, naming Ozempic or Wegovy without specifying what the plaintiff alleges. Both drugs share the same active ingredient, semaglutide, so the eventual claims could touch either the diabetes or weight-loss version, or both. Novo Nordisk has faced a growing number of suits tied to its GLP-1 products, and this filing adds to that count without yet adding clarity. Until the court releases more, this case remains a marker of pending litigation rather than a signal of any particular risk.
David v. Novo Nordisk is the third case tracked this week, and it names the same manufacturer without identifying which drug or drugs are involved. That the company faces two separate suits in one week is notable on its own, even before any claims are made public. Multiple pending cases against the same manufacturer can sometimes move faster once one court unseals its filing, since plaintiffs' attorneys often watch each other's cases closely. For now, this filing stands alongside Cardenas as a second open matter against Novo Nordisk with no public detail yet attached.
None of these three filings currently tell patients or prescribers what went wrong, if anything, with these medications. That absence of detail is not unusual this early in litigation, and it does not by itself suggest a safety problem with Mounjaro, Zepbound, Ozempic, or Wegovy. Readers who take these medications may want to check back as court records are unsealed, and those with questions about their own treatment should raise them with their prescriber rather than draw conclusions from a pending lawsuit alone. GLP1Laws will update these entries as the underlying claims become public.
Key details
Scully v. Eli Lilly targets Mounjaro or Zepbound, but claims remain sealed for now.
A second suit, Cardenas v. Novo Nordisk, covers Ozempic or Wegovy without public details.
David v. Novo Nordisk marks a third pending case, its claims still undisclosed.
Originally published on GLP1Laws.
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.